Drug Profile


Alternative Names: CS-3150; XL-550

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Daiichi Sankyo Company
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension; Hyperaldosteronism; Hypertension
  • Phase II Diabetic nephropathies
  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 09 Jun 2017 Chemical structure information added
  • 25 May 2017 Daiichi Sankyo completes a phase I pharmacokinetics trial in Japan (JapicCTI-163452)
  • 24 Apr 2017 Daiichi Sankyo completes a phase I trial for drug-drug interaction trial in Japan (PO) (JapicCTI163443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top